Abstract 165P
Background
Lung cancer is the most common cancer in men (14.3%) and 3rd most common cancer in female (8.4%) but account for overall highest cancer related mortality (18%). In India, lung cancer is 4th most common cancer both in incidence and cancer related death. NSCLC is the most common type accounting about 80-85% cases and among these adenocarcinoma accounts for more than half and is further defined according to different molecular subtypes by the identification of oncogenic drivers. With recent advances in the knowledge of NSCLC biology, various oncogenic driver mutations are identified which causes aberrant activation of intracellular signaling pathways associated with the sustained growth of lung cancer cells. Research objectives: Evaluation the mutational profile of NSCLC with broad panel-based next-generation sequencing.
Methods
The study was a hospital based prospective, cross sectional descriptive study conducted at a tertiary care center in Northeast India done during the period from 1st january,2022 to 31st December,2022. Ninteen cases of histologically proven meatstatic NSCLC in core biopsy were included in this study.
Results
The age of patients with NSCLC in our study ranged from 48 to 80 years with mean age of 64.36(+/-9.82) years. Majority of the patients in our study were from the age category 71-80 years (37%) Male to female ratio was 19:1 (95% vs 5%). 73.3% of cases were chronic smokers while 26.3% were nonsmokers with smoker non-smoker ratio of 2.79:1.100% of cases presented in late stage (Stages IV). Regarding biomarker profile of NSCLC in our study, EGFR mutation positivity was seen in 10.5%.ALK rearrangement was positive in 5.3% of patients. In our study PD-L1 expression positivity was57.9% and among these patients,18.2% has TPS>50% whereas 81.8% showed TPS<50%.
Conclusions
Adenocarcinoma is the predominant histological subtype of NSCLC in the region of NE India, with a high proportion of cases harboring EGFR mutation. Moreover, NSCLC is characterized with unique mutations and cannot be generalized in larger context. So, study with larger sample size should be encouraged for evaluation of molecular profile of NSCLC in this region.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Assam Medical College, Dibrugarh.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
157P - PCM4EU academy: An educational program for precision oncology
Presenter: Loic Verlingue
Session: Cocktail & Poster Display session
Resources:
Abstract
158P - Enhancing the communication of genomic results: Understanding patient and clinician perspectives
Presenter: Eleanor Johnston
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - CICLADES-CE study: Genomic signatures detected in DNA from FFPE samples of patients with advanced or metastatic breast cancers treated with anti-aromatase and CDK4/6 inhibitors
Presenter: Margaux BETZ
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - PDL1 expression and its relation to EML4-ALK gene variants in metastatic lung adenocarcinoma: A single-center real-world experience
Presenter: Santhosh Meedimale
Session: Cocktail & Poster Display session
Resources:
Abstract
163P - Impact of genomic sequencing data on treatment decisions in advanced breast cancer (ABC)
Presenter: Sviatoslav Chekhun
Session: Cocktail & Poster Display session
Resources:
Abstract
164P - Clinical utility of comprehensive molecular profiling tests for advanced gastrointestinal tumors
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Targeted next-generation sequencing as reliable detection of genetic profile for cancer treatment to guide oncologists in Pakistan
Presenter: Zeeshan Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Molecular analysis of gastrointestinal stromal tumor (GIST): The experience of Regina Elena National Cancer Institute
Presenter: Andrea Torchia
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Usefulness of liquid biopsy in the management of patients with advanced or metastatic pancreatic cancer
Presenter: Jorge Iranzo Barreira
Session: Cocktail & Poster Display session
Resources:
Abstract